JP2015063487A - External composition - Google Patents
External composition Download PDFInfo
- Publication number
- JP2015063487A JP2015063487A JP2013198248A JP2013198248A JP2015063487A JP 2015063487 A JP2015063487 A JP 2015063487A JP 2013198248 A JP2013198248 A JP 2013198248A JP 2013198248 A JP2013198248 A JP 2013198248A JP 2015063487 A JP2015063487 A JP 2015063487A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pqq
- salt
- acid
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims abstract description 102
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 239000006097 ultraviolet radiation absorber Substances 0.000 claims abstract description 22
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 claims description 8
- 125000005427 anthranyl group Chemical group 0.000 claims description 7
- 239000006096 absorbing agent Substances 0.000 claims description 6
- 150000003918 triazines Chemical class 0.000 claims description 6
- 150000002461 imidazolidines Chemical class 0.000 claims description 5
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 3
- -1 imidazolopyrroloquinoline compound Chemical class 0.000 description 30
- 239000002537 cosmetic Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical group C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 description 3
- 229940105990 diglycerin Drugs 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 description 3
- 229960002248 meradimate Drugs 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- IYAZLDLPUNDVAG-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)phenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 IYAZLDLPUNDVAG-UHFFFAOYSA-N 0.000 description 2
- MJBPWNFFVIYFNJ-UHFFFAOYSA-N 2-ethylhexyl 3-(4-benzylidene-3,5-dimethoxy-2-oxoimidazolidin-1-yl)propanoate Chemical group COC1C(N(C(N1CCC(=O)OCC(CCCC)CC)=O)OC)=CC1=CC=CC=C1 MJBPWNFFVIYFNJ-UHFFFAOYSA-N 0.000 description 2
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000006750 UV protection Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 108010006161 conchiolin Proteins 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZNVKGUVDRSSWHV-UHFFFAOYSA-L zinc;4-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 ZNVKGUVDRSSWHV-UHFFFAOYSA-L 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- FRGIOIALHUOUTR-UHFFFAOYSA-N 2-[4-(diethylamino)-2-hydroxybenzoyl]hexyl benzoate Chemical group C=1C=C(N(CC)CC)C=C(O)C=1C(=O)C(CCCC)COC(=O)C1=CC=CC=C1 FRGIOIALHUOUTR-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- DDGPBVIAYDDWDH-UHFFFAOYSA-N 3-[dodecyl(dimethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC(O)CS([O-])(=O)=O DDGPBVIAYDDWDH-UHFFFAOYSA-N 0.000 description 1
- RIAJTMUAPNIDSS-UHFFFAOYSA-N 3-aminopropan-1-ol;hydron;chloride Chemical compound Cl.NCCCO RIAJTMUAPNIDSS-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- QCGVLCYLNVOQHL-UHFFFAOYSA-N C(CC)(=O)O.COC(CN1C(NC(C1(OC)OC)=CC1=CC=CC=C1)=O)CCCC Chemical compound C(CC)(=O)O.COC(CN1C(NC(C1(OC)OC)=CC1=CC=CC=C1)=O)CCCC QCGVLCYLNVOQHL-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical class C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- AWVKYDMYXARGOC-UHFFFAOYSA-N N',N'-diethylpropane-1,3-diamine octadecanoic acid Chemical compound CCN(CC)CCCN.CCCCCCCCCCCCCCCCCC(O)=O AWVKYDMYXARGOC-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 108010075308 N-palmitoyl-seryl-seryl-asparaginyl-alanine Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002871 Tectona grandis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000004110 Zinc silicate Substances 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- GNKTZDSRQHMHLZ-UHFFFAOYSA-N [Si].[Si].[Si].[Ti].[Ti].[Ti].[Ti].[Ti] Chemical compound [Si].[Si].[Si].[Ti].[Ti].[Ti].[Ti].[Ti] GNKTZDSRQHMHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960002298 aminohydroxybutyric acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 229960004101 bemotrizinol Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- KZLCXWIDONWFBK-UHFFFAOYSA-N butylcarbamic acid 1-iodopropane Chemical compound C(CC)I.C(CCC)NC(O)=O KZLCXWIDONWFBK-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- JIHMVMRETUQLFD-UHFFFAOYSA-N cerium(3+);dioxido(oxo)silane Chemical compound [Ce+3].[Ce+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JIHMVMRETUQLFD-UHFFFAOYSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- NAPSCFZYZVSQHF-UHFFFAOYSA-N dimantine Chemical compound CCCCCCCCCCCCCCCCCCN(C)C NAPSCFZYZVSQHF-UHFFFAOYSA-N 0.000 description 1
- 229950010007 dimantine Drugs 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- NNSWOABHNWRKDR-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine;octadecanoic acid Chemical compound CCN(CC)CCN.CCCCCCCCCCCCCCCCCC(O)=O NNSWOABHNWRKDR-UHFFFAOYSA-N 0.000 description 1
- RVRFYZGKUZFYAH-UHFFFAOYSA-N n',n'-dimethylpropane-1,3-diamine;octadecanoic acid Chemical compound CN(C)CCCN.CCCCCCCCCCCCCCCCCC(O)=O RVRFYZGKUZFYAH-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000014537 nerve growth factor production Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- SWZDQOUHBYYPJD-UHFFFAOYSA-N tridodecylamine Chemical compound CCCCCCCCCCCCN(CCCCCCCCCCCC)CCCCCCCCCCCC SWZDQOUHBYYPJD-UHFFFAOYSA-N 0.000 description 1
- NVSDADJBGGUCLP-UHFFFAOYSA-N trisulfur Chemical compound S=S=S NVSDADJBGGUCLP-UHFFFAOYSA-N 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- XSMMCTCMFDWXIX-UHFFFAOYSA-N zinc silicate Chemical compound [Zn+2].[O-][Si]([O-])=O XSMMCTCMFDWXIX-UHFFFAOYSA-N 0.000 description 1
- 235000019352 zinc silicate Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、ピロロキノリンキノン(以下、「PQQ」と略称することがある)、又は薬学的若しくは生理学的に許容されるその塩(以下、「その塩」と略称することがある)を含み、化粧品、医薬部外品、又は医薬品として使用される外用組成物に関する。 The present invention includes pyrroloquinoline quinone (hereinafter sometimes abbreviated as “PQQ”), or a pharmaceutically or physiologically acceptable salt thereof (hereinafter sometimes abbreviated as “salt thereof”), The present invention relates to a composition for external use used as a cosmetic, a quasi-drug, or a pharmaceutical product.
PQQは、植物、動物、及び微生物など広く生物界に存在し、エネルギー獲得に必須である酸化還元の補酵素として機能している。
PQQには、多くの生理活性があることが知られており、医薬品、医薬部外品、化粧品、又はサプリメントの有効成分としての使用が期待されている。このような生理活性として、活性酸素及びラジカルの消去作用、細胞増殖促進作用、紫外線吸収作用、神経成長因子産生促進作用、脳機能改善作用、育毛作用、顔色改善作用、メラニン産生抑制又は美白作用、ミトコンドリア賦活作用、及び抗疲労作用などが知られている。
PQQ exists widely in the living world such as plants, animals, and microorganisms, and functions as a redox coenzyme essential for energy acquisition.
PQQ is known to have many physiological activities and is expected to be used as an active ingredient in pharmaceuticals, quasi drugs, cosmetics, or supplements. As such physiological activity, active oxygen and radical scavenging action, cell growth promoting action, ultraviolet absorption action, nerve growth factor production promoting action, brain function improving action, hair growth action, facial color improving action, melanin production suppression or whitening action, Mitochondrial activation and anti-fatigue effects are known.
一方で、PQQは非常に高い反応性を示すため、製剤を調製する際の配合成分の種類によっては、PQQ分解が促進されるなど非常に不安定であることが知られている。例えば、PQQは、アミノ酸、ペプチド、及びタンパク質などのアミノ基含有物質と容易に反応し、その構造内にイミダゾール骨格を形成してイミダゾロピロロキノリン(imidazolopyrroloquinoline)化合物になることが報告されている。 On the other hand, since PQQ shows very high reactivity, it is known that PQQ decomposition is accelerated, depending on the type of compounding ingredients in preparing the preparation. For example, it has been reported that PQQ easily reacts with amino group-containing substances such as amino acids, peptides, and proteins, and forms an imidazole skeleton in the structure to become an imidazolopyrroloquinoline compound.
PQQの分解により、製剤中のPQQ含量が低下すると、PQQの所期の効果が得られない。また、PQQの分解や反応により、製剤の性状が変化して使用感に悪影響を及ぼす場合がある。例えば、クリームや乳液では、製剤の変色、液だれ、成分の分離などが発生した場合、視覚的に、また使用感の点で、商品の価値を損ねる。 If the PQQ content in the preparation decreases due to the decomposition of PQQ, the desired effect of PQQ cannot be obtained. In addition, degradation of PQQ and reaction may change the properties of the preparation and adversely affect the feeling of use. For example, in the case of a discoloration, dripping, or separation of ingredients in a cream or milky lotion, the value of the product is impaired visually and in terms of usability.
一般に、製剤中の特定の成分の安定性を向上させる試みとして、その特定成分やその成分を不安定にする成分に皮膜を形成させて両成分間の接触による分解反応を抑制する方法、誘導体にする方法、遮光容器に収容する方法、その特定成分を含む組成物とその成分を不安定にする成分を含む組成物とを別々の容器に収容しておき、使用前に両組成物を混合して使用する方法などが試みられている。 In general, as an attempt to improve the stability of a specific component in a formulation, a method or derivative that suppresses a decomposition reaction caused by contact between the two components by forming a film on the specific component or a component that makes the component unstable Method, method of storing in a light-shielding container, composition containing the specific component and composition containing the component that destabilizes the component are stored in separate containers, and both compositions are mixed before use. There have been attempts to use them.
しかし、従来試みられている方法は、製剤化の自由度が著しく制限されたり、容器のコストが高くなったりするなど、商品化に難点がある。 However, conventional methods have difficulty in commercialization, for example, the degree of freedom of formulation is significantly limited and the cost of the container is increased.
また、塩酸ピリドキシンを含む組成物に、紫外線吸収剤とジブチルヒドロキシトルエンを配合して保存安定性を向上させる方法も知られているが(特許文献1)、紫外線吸収剤のみでは実用上十分に熱分解を抑制する効果は見られない。また、PQQの熱安定性を向上させることは全く知られていなかった。 In addition, a method for improving storage stability by blending a composition containing pyridoxine hydrochloride with an ultraviolet absorber and dibutylhydroxytoluene is known (Patent Document 1). The effect of suppressing decomposition is not seen. Further, it has not been known at all to improve the thermal stability of PQQ.
本発明は、PQQ又はその塩を含む外用組成物であって、PQQ又はその塩の安定性に優れる外用組成物を提供することを課題とする。 This invention makes it a subject to provide the composition for external use containing PQQ or its salt, Comprising: The external composition which is excellent in stability of PQQ or its salt.
本発明者は、上記課題を解決するために研究を重ね、外用組成物中のPQQ又はその塩の熱安定性を向上させるために、トリアジン誘導体、ジベンゾイルメタン誘導体、安息香酸誘導体、アントラニル誘導体、イミダゾリジン誘導体である紫外線吸収剤のいずれかを配合するだけで、PQQ又はその塩の熱安定性が著しく向上し、全く又は殆ど分解しない外用組成物が得られることを見出した。 In order to solve the above-mentioned problems, the present inventor has conducted research, and in order to improve the thermal stability of PQQ or a salt thereof in a composition for external use, a triazine derivative, a dibenzoylmethane derivative, a benzoic acid derivative, an anthranyl derivative, It has been found that by adding only one of the ultraviolet absorbers that are imidazolidine derivatives, the thermal stability of PQQ or a salt thereof is remarkably improved, and an external composition that does not decompose at all or hardly can be obtained.
本発明は、上記知見に基づき完成されたものであり、以下の外用組成物を提供する。
項1. (a)ピロロキノリンキノン、又は薬学的若しくは生理的に許容されるその塩、及び(b)紫外線吸収剤を含む外用組成物。
項2. (b)紫外線吸収剤が、トリアジン誘導体、ジベンゾイルメタン誘導体、安息香酸誘導体、アントラニル誘導体、イミダゾリジン誘導体からなる群より選ばれる少なくとも1種の紫外線吸収剤を含む項1に記載の外用組成物。
項3. トリアジン誘導体が、2,4−ビス−〔{4−(2−エチルヘキシルオキシ)−2−ヒドロキシ}−フェニル〕−6−(4−メトキシフェニル)−1,3,5−トリアジン、2,2’-メチレンビス(6-(2H-ベンゾトリアゾール-2-イル)-4-(1,1,3,3-テトラメチルブチル)フェノールである項1〜2に記載の外用組成物。
項4. ジベンゾイルメタン誘導体が、4−tert−ブチル−4’−メトキシジベンゾイルメタンである項1又は2に記載の外用組成物。
項5. 安息香酸誘導体が、2−〔4−(ジエチルアミノ)−2−ヒドロキシベンゾイル〕安息香酸ヘキシルである項1〜2に記載の外用組成物。
項6. アントラニル誘導体が、アントラニル酸メンチルである項1又は2に記載の外用組成物。
項7. イミダゾリジン誘導体が、ジメトキシベンジリデンオキソイミダゾリジンプロピオン酸2−エチルヘキシルである項1又は2に記載の外用組成物。
項8. (b)紫外線吸収剤を、組成物の全量に対して、0.01〜30重量%含む項1〜7の何れかに記載の外用組成物。
項9. 紫外線からの皮膚又は毛髪の保護用である項1〜8の何れかに記載の外用組成物。
This invention is completed based on the said knowledge, and provides the following external compositions.
Item 1. An external composition comprising (a) pyrroloquinoline quinone, or a pharmaceutically or physiologically acceptable salt thereof, and (b) an ultraviolet absorber.
Item 2. (b) The external composition according to item 1, wherein the ultraviolet absorber comprises at least one ultraviolet absorber selected from the group consisting of a triazine derivative, a dibenzoylmethane derivative, a benzoic acid derivative, an anthranyl derivative, and an imidazolidine derivative.
Item 3. The triazine derivative is 2,4-bis-[{4- (2-ethylhexyloxy) -2-hydroxy} -phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine, 2,2 ′ Item 3. The composition for external use according to Item 1 or 2, which is methylenebis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol.
Item 4. Item 3. The composition for external use according to Item 1 or 2, wherein the dibenzoylmethane derivative is 4-tert-butyl-4'-methoxydibenzoylmethane.
Item 5. Item 3. The externally applied composition according to Item 1-2, wherein the benzoic acid derivative is 2- [4- (diethylamino) -2-hydroxybenzoyl] hexyl benzoate.
Item 6. Item 3. The external composition according to Item 1 or 2, wherein the anthranyl derivative is menthyl anthranilate.
Item 7. Item 3. The externally applied composition according to Item 1 or 2, wherein the imidazolidine derivative is 2-ethylhexyl dimethoxybenzylideneoxoimidazolidinepropionate.
Item 8. (b) The external composition in any one of claim | item 1 -7 containing 0.01-30 weight% of ultraviolet absorbers with respect to the whole quantity of a composition.
Item 9. Item 9. The composition for external use according to any one of Items 1 to 8, which is used for protecting skin or hair from ultraviolet rays.
本願発明に係る外用組成物は、高い紫外線防御効果を有すると同時に、PQQの熱に対する安定性にも優れており、長期間安定に保存可能である。 The composition for external use according to the present invention has a high UV protection effect and at the same time is excellent in the stability of PQQ to heat, and can be stored stably for a long period of time.
以下、本発明を詳細に説明する。
本発明の外用組成物は、(a)PQQ又はその塩、(b)紫外線吸収剤を含む外用組成物である。
Hereinafter, the present invention will be described in detail.
The external composition of the present invention is an external composition containing (a) PQQ or a salt thereof and (b) an ultraviolet absorber.
(a)PQQ又はその塩
PQQは動物、植物、及び細菌など多様な生物体内に存在するので、種々の生物から抽出できる。また、PQQは、市販品を購入できる。
PQQの生理学的又は薬学的に許容されるその塩としては、ナトリウム塩、カリウム塩、及びリチウム塩のようなアルカリ金属塩;カルシウム塩、及びマグネシウム塩のようなアルカリ土類金属塩などが挙げられる。塩の中では、ナトリウム塩、カリウム塩、リチウム塩、カルシウム塩、及びマグネシウム塩が好ましい。
(a) PQQ or its salt PQQ exists in various organisms such as animals, plants, and bacteria, and therefore can be extracted from various organisms. Moreover, PQQ can purchase a commercial item.
Physiologically or pharmaceutically acceptable salts of PQQ include alkali metal salts such as sodium salt, potassium salt, and lithium salt; alkaline earth metal salts such as calcium salt and magnesium salt, and the like. . Among the salts, sodium salt, potassium salt, lithium salt, calcium salt, and magnesium salt are preferable.
組成物中のPQQ又はその塩の含有量は、組成物の全量に対して、0.00001重量%以上が好ましく、0.0001重量%以上がより好ましく、0.001重量%以上がさらにより好ましい。上記範囲であれば、化粧品、医薬部外品、医薬外用剤の通常使用量で、PQQ又はその塩の生理活性が十分に得られる。
また、組成物中のPQQ又はその塩の含有量は、組成物の全量に対して、1重量%以下が好ましく、0.3重量%以下がより好ましく、0.1重量%以下がさらにより好ましく、0.05重量%以下がさらにより好ましく、0.03重量%以下がさらにより好ましい。上記範囲であれば、製剤中での溶解性が良好で、また外用組成物としての外観の点で優れたものとなる。
The content of PQQ or a salt thereof in the composition is preferably 0.00001% by weight or more, more preferably 0.0001% by weight or more, and still more preferably 0.001% by weight or more with respect to the total amount of the composition. . If it is the said range, the physiological activity of PQQ or its salt will fully be obtained by the normal usage-amount of cosmetics, a quasi-drug, and a pharmaceutical external preparation.
Further, the content of PQQ or a salt thereof in the composition is preferably 1% by weight or less, more preferably 0.3% by weight or less, still more preferably 0.1% by weight or less, based on the total amount of the composition. 0.05 wt% or less is even more preferable, and 0.03 wt% or less is even more preferable. If it is the said range, the solubility in a formulation will be favorable, and it will become the thing excellent in the point of the external appearance as a composition for external use.
(b)紫外線吸収剤
紫外線吸収剤としては、トリアジン誘導体、ジベンゾイルメタン誘導体、安息香酸誘導体、アントラニル誘導体、イミダゾリン誘導体等の有機紫外線吸収剤が挙げられる。
(b) Ultraviolet absorbers Examples of the ultraviolet absorber include organic ultraviolet absorbers such as triazine derivatives, dibenzoylmethane derivatives, benzoic acid derivatives, anthranyl derivatives, and imidazoline derivatives.
トリアジン誘導体の例としては、2,4−ビス−〔{4−(2−エチルヘキシルオキシ)−2−ヒドロキシ}−フェニル〕−6−(4−メトキシフェニル)−1,3,5−トリアジン(チノソルブS、BASFジャパン社)、2,2’-メチレンビス(6-(2H-ベンゾトリアゾール-2-イル)-4-(1,1,3,3-テトラメチルブチル)フェノール(チノソルブM、BASFジャパン社)等が挙げられる。 Examples of triazine derivatives include 2,4-bis-[{4- (2-ethylhexyloxy) -2-hydroxy} -phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine (Tinosolve). S, BASF Japan), 2,2'-methylenebis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol (Tinosolve M, BASF Japan) ) And the like.
ジベンゾイルメタン誘導体の例としては、4−tert−ブチル−4’−メトキシジベンゾイルメタン(パルソール1789、DSMニュートリションジャパン社)等が挙げられる。 Examples of the dibenzoylmethane derivative include 4-tert-butyl-4'-methoxydibenzoylmethane (Pulsol 1789, DSM Nutrition Japan).
安息香酸誘導体の例としては、2−[−4−(ジエチルアミノ)−2−ヒドロキシベンゾイル]安息香酸ヘキシルエステル(ユビナールAプラス、BASFジャパン社)等が挙げられる。 Examples of the benzoic acid derivative include 2-[-4- (diethylamino) -2-hydroxybenzoyl] benzoic acid hexyl ester (Ubinal A plus, BASF Japan).
アントラニル誘導体の例としては、アントラニル酸メンチル等が挙げられる。 Examples of anthranyl derivatives include menthyl anthranilate.
イミダゾリジン誘導体の例としては、ジメトキシベンジリデンオキソイミダゾリジンプロピオン酸2−エチルヘキシル等が挙げられる。 Examples of imidazolidine derivatives include 2-methoxyhexyl dimethoxybenzylideneoxoimidazolidine propionate.
好ましい紫外線吸収剤としては、アントラニル酸メンチルのようなアントラニル誘導体;ジメトキシベンジリデンオキソイミダゾリジンプロピオン酸2−エチルヘキシルのようなイミダゾリジン誘導体;2−〔4−(ジエチルアミノ)−2−ヒドロキシベンゾイル〕安息香酸ヘキシルのような安息香酸誘導体;4−tert−ブチル−4’−メトキシジベンゾイルメタンのようなジベンゾイルメタン誘導体; 2,4−ビス−〔{4−(2−エチルヘキシルオキシ)−2−ヒドロキシ}−フェニル〕−6−(4−メトキシフェニル)−1,3,5−トリアジン、2,2’-メチレンビス(6-(2H-ベンゾトリアゾール-2-イル)-4-(1,1,3,3-テトラメチルブチル)フェノールのようなトリアジン誘導体などが挙げられる。
中でも、安息香酸誘導体、ジベンゾイルメタン誘導体、トリアジン誘導体が好ましく、2−〔4−(ジエチルアミノ)−2−ヒドロキシベンゾイル〕安息香酸ヘキシル、4−tert−ブチル−4’−メトキシジベンゾイルメタン、2,4−ビス−〔{4−(2−エチルヘキシルオキシ)−2−ヒドロキシ}−フェニル〕−6−(4−メトキシフェニル)−1,3,5−トリアジンがより好ましい。
Preferred UV absorbers include anthranyl derivatives such as menthyl anthranilate; imidazolidine derivatives such as 2-ethylhexyl dimethoxybenzylideneoxoimidazolidinepropionate; hexyl 2- [4- (diethylamino) -2-hydroxybenzoyl] benzoate Benzoic acid derivatives such as; dibenzoylmethane derivatives such as 4-tert-butyl-4′-methoxydibenzoylmethane; 2,4-bis-[{4- (2-ethylhexyloxy) -2-hydroxy}- Phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine, 2,2'-methylenebis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3 -Triazine derivatives such as -tetramethylbutyl) phenol.
Of these, benzoic acid derivatives, dibenzoylmethane derivatives, and triazine derivatives are preferred, and hexyl 2- [4- (diethylamino) -2-hydroxybenzoyl] benzoate, 4-tert-butyl-4′-methoxydibenzoylmethane, 2, 4-bis-[{4- (2-ethylhexyloxy) -2-hydroxy} -phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine is more preferred.
紫外線吸収剤は、1種を単独で、又は2種以上を組み合わせて使用できる。 An ultraviolet absorber can be used individually by 1 type or in combination of 2 or more types.
外用組成物中の紫外線吸収剤の含有量は、組成物の全量に対して、0.01重量%以上が好ましく、0.05重量%以上がより好ましく、0.1重量%以上がさらにより好ましい。上記範囲であれば、PQQ又はその塩の熱安定性が良好になる。
また、外用組成物中の紫外線吸収剤の含有量は、組成物の全量に対して、30重量%以下が好ましく、10重量%以下がより好ましく、7重量%以下がさらにより好ましい。上記範囲であれば、べたつき、きしみが発生せず、使用感が良好な組成物となる。
The content of the ultraviolet absorber in the external composition is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, and still more preferably 0.1% by weight or more based on the total amount of the composition. . If it is the said range, the thermal stability of PQQ or its salt will become favorable.
In addition, the content of the ultraviolet absorber in the external composition is preferably 30% by weight or less, more preferably 10% by weight or less, and even more preferably 7% by weight or less based on the total amount of the composition. If it is the said range, stickiness and a squeak will not generate | occur | produce and it will become a composition with a favorable usability | use_condition.
また、PQQ又はその塩の含有量に対する紫外線吸収剤の含有量の比率は、PQQ又はその塩1重量部に対して、0.2重量部以上が好ましく、1重量部以上がより好ましく、2重量部以上がさらにより好ましい。上記範囲であれば、PQQ又はその塩の熱安定性が良好になる。
また、PQQ又はその塩の含有量に対する紫外線吸収剤の含有量の比率は、PQQ又はその塩1重量部に対して、30000重量部以下が好ましく、10000重量部以下がより好ましく、7000重量部以下がさらにより好ましい。上記範囲であれば、PQQ又はその塩の熱安定性が良好になる。
Further, the ratio of the content of the ultraviolet absorber to the content of PQQ or a salt thereof is preferably 0.2 parts by weight or more, more preferably 1 part by weight or more, with respect to 1 part by weight of PQQ or a salt thereof. Part or more is even more preferable. If it is the said range, the thermal stability of PQQ or its salt will become favorable.
Further, the ratio of the content of the ultraviolet absorber to the content of PQQ or a salt thereof is preferably 30000 parts by weight or less, more preferably 10000 parts by weight or less, and 7000 parts by weight or less with respect to 1 part by weight of PQQ or a salt thereof. Is even more preferred. If it is the said range, the thermal stability of PQQ or its salt will become favorable.
pH
本発明の組成物のpHは、2.5以上が好ましく、3以上がより好ましく、4以上がさらにより好ましい。また、9以下が好ましく、8.5以下がより好ましく、8以下がさらにより好ましい。上記範囲であれば、PQQ及びその誘導体又はその塩が安定に保たれる。
pH
The pH of the composition of the present invention is preferably 2.5 or more, more preferably 3 or more, and even more preferably 4 or more. Moreover, 9 or less is preferable, 8.5 or less is more preferable, and 8 or less is still more preferable. If it is the said range, PQQ and its derivative (s) or its salt will be maintained stably.
製剤形態
本発明の外用組成物は、(a)PQQ又はその塩、(b)紫外線吸収剤を含む紫外線吸収剤を、医薬品、医薬部外品、又は化粧品等の外用組成物に使用できる、薬学的又は生理学的に許容される基剤又は担体、及び必要に応じて医薬品、医薬部外品、又は化粧品等の外用組成物に使用できる添加剤と共に混合して、医薬品、医薬部外品、又は化粧品用の外用組成物とすることができる。
Formulation Form The composition for external use of the present invention is a pharmaceutical composition in which (a) PQQ or a salt thereof and (b) an ultraviolet absorber containing an ultraviolet absorber can be used in an external composition such as a pharmaceutical, a quasi-drug, or a cosmetic. Or a pharmaceutical or quasi-drug, or a pharmaceutical or quasi-drug, or a pharmaceutical or quasi-drug, or an additive that can be used in a topical composition such as a pharmaceutical, quasi-drug, or cosmetic if necessary It can be set as the external composition for cosmetics.
医薬品用の外用組成物の形態は特に限定されず、例えば、液剤、懸濁剤、乳剤、クリーム剤、軟膏剤、ゲル剤、リニメント剤、ローション剤、及びエアゾール剤などが挙げられる。これらの製剤は、第16改正日本薬局方製剤総則に記載の方法等に従い製造することができる。
医薬部外品又は化粧品用の外用組成物とする場合も、上記の医薬品と同様の形態にすることができる。また、それ以外にも、スティック剤、及び不織布に薬液を含浸させたシート剤等が挙げられる。
The form of the external composition for pharmaceuticals is not particularly limited, and examples thereof include liquids, suspensions, emulsions, creams, ointments, gels, liniments, lotions, and aerosols. These preparations can be manufactured according to the method described in the 16th revised Japanese Pharmacopoeia General Rules for Preparations.
Also when it is set as the composition for external use for quasi drugs or cosmetics, it can be made into the same form as said pharmaceutical. In addition, a stick agent, a sheet agent obtained by impregnating a non-woven fabric with a chemical solution, and the like can be given.
医薬部外品又は化粧品用の外用組成物とする場合の用途としては具体的には、例えば、化粧水、乳液、ジェル、クリーム、美容液、日焼け止め用化粧料、パック、マスク、ハンドクリーム、リップクリーム、ボディローション、及びボディークリームのような基礎化粧料;ファウンデーション、口紅、チークカラー、及びアイカラーのようなメークアップ化粧料;並びに洗顔料、メイク落とし、ボディーシャンプー、シャンプー、リンス、及びトリートメントのような洗浄用化粧料などが挙げられる。また、これら基礎化粧料、メイクアップ化粧料、及び洗浄用化粧料などの製剤機能を少なくとも2つ以上を1つの製剤にまとめた多機能型製剤も挙げられる。 Specifically, as an application in the case of a quasi-drug or cosmetic composition for external use, for example, lotion, emulsion, gel, cream, serum, sunscreen cosmetic, pack, mask, hand cream, Basic cosmetics such as lip balms, body lotions, and body creams; makeup cosmetics such as foundations, lipsticks, teak colors, and eye colors; and facial cleansers, makeup removers, body shampoos, shampoos, rinses, and treatments And cosmetics for cleaning. In addition, multifunctional preparations in which at least two preparation functions such as basic cosmetics, makeup cosmetics, and cleaning cosmetics are combined into one preparation are also included.
基剤又は担体
医薬品、医薬部外品、又は化粧品等の外用組成物に使用される、薬学的又は生理学的に許容される基剤又は担体としては、スクワラン、ワセリン、α−オレフィンオリゴマー、及び軽質流動パラフィンのような炭化水素;セタノール、セトステアリルアルコール、ステアリルアルコール、及びベヘニルアルコールのような高級アルコール;コレステロール、フィトステロール、及びヒドロキシステアリン酸フィトステリルのようなステロール類;ラノリン、オレンジラフィー油、スクワラン、及び馬油のような動物油;エチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、カチオン化グアガム、及びアセチル化ヒアルロン酸のような天然高分子誘導体;ポリビニルピロリドン、カルボキシビニルポリマー、及びアクリル酸メタクリル酸アルキル共重合体のような合成高分子;カラギーナン、アルギン酸、セルロース、グアーガム、クインスシード、デキストラン、ジェランガム、及びヒアルロン酸のような天然高分子;ミリスチン酸イソプロピル、ミリスチン酸オクチルドデシル、パルミチン酸イソプロピル、パルミチン酸セチル、イソノナン酸イソノニル、テトラ2−エチルヘキサン酸ペンタエリスリット、ホホバ油、及びトリ(カプリル酸/カプリン酸)グリセリル、トリエチルヘキサノインのようなエステル類;デキストリン、及びマルトデキストリンのような多糖類;エタノール、及びイソプロパノールのような低級アルコール;エチレングリコールモノメチルエーテル、のようなグリコールエーテル;ポリエチレングリコール、プロピレングリコール、1,3-ブチレングリコール、グリセリン、イソプレングリコール、ジグリセリン、及びジプロピレングリコールなどの多価アルコール;コハク酸、グリコール酸、グルコン酸、及びクエン酸などの有機酸;並びに水などの水系基剤などが挙げられる。
Bases or carriers Pharmaceutically or physiologically acceptable bases or carriers used in pharmaceutical compositions, quasi-drugs, cosmetics, etc., include squalane, petrolatum, α-olefin oligomers, and light Hydrocarbons such as liquid paraffin; higher alcohols such as cetanol, cetostearyl alcohol, stearyl alcohol, and behenyl alcohol; sterols such as cholesterol, phytosterol, and phytosteryl hydroxystearate; lanolin, orange raffii oil, squalane, and horses Animal oils such as oils; natural polymer derivatives such as ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, cationized guar gum, and acetylated hyaluronic acid; polyvinylpyrrolidone, carboxy Nyl polymers and synthetic polymers such as alkyl methacrylate methacrylate copolymers; natural polymers such as carrageenan, alginic acid, cellulose, guar gum, quince seed, dextran, gellan gum, and hyaluronic acid; isopropyl myristate, octyl myristate Dodecyl, isopropyl palmitate, cetyl palmitate, isononyl isononanoate, pentaerythritol tetra-2-ethylhexanoate, jojoba oil, and esters such as tri (caprylic / capric) glyceryl, triethylhexanoin; dextrin, and Polysaccharides such as maltodextrin; lower alcohols such as ethanol and isopropanol; glycol ethers such as ethylene glycol monomethyl ether; polyethylene glycol Polyhydric alcohols such as cole, propylene glycol, 1,3-butylene glycol, glycerin, isoprene glycol, diglycerin, and dipropylene glycol; organic acids such as succinic acid, glycolic acid, gluconic acid, and citric acid; and water And an aqueous base.
中でも、多価アルコール、高級アルコール、炭化水素、エステル類、シリコーン油、及び有機酸が好ましく、多価アルコールがより好ましい。多価アルコールの中では、1,3-ブチレングリコール、プロピレングリコール、イソプレングリコール、グリセリン、ジグリセリン、及びジプロピレングリコールが好ましく、1,3-ブチレングリコール、プロピレングリコール、グリセリン、及びジグリセリンがさらに好ましい。本発明の組成物の好ましい例として、基剤として低級アルコール及び/又は多価アルコールを含む液剤、ローション剤、クリーム剤、ゲル剤、乳剤、及び軟膏が挙げられる。 Among these, polyhydric alcohols, higher alcohols, hydrocarbons, esters, silicone oils, and organic acids are preferable, and polyhydric alcohols are more preferable. Among the polyhydric alcohols, 1,3-butylene glycol, propylene glycol, isoprene glycol, glycerin, diglycerin, and dipropylene glycol are preferable, and 1,3-butylene glycol, propylene glycol, glycerin, and diglycerin are more preferable. . Preferable examples of the composition of the present invention include solutions, lotions, creams, gels, emulsions, and ointments containing a lower alcohol and / or a polyhydric alcohol as a base.
本発明の外用組成物が水を含む場合のその含有量は、組成物の全量に対して、5重量%以上が好ましく、10重量%以上がより好ましく、20%以上がさらにより好ましい。また、80重量%以下が好ましく、70重量%以下がより好ましく、50重量%以下がさらにより好ましい。本発明の外用組成物が乳化組成物である場合、O/W型であってもよく、W/O型であってもよい。
基剤又は担体は、1種を単独で、又は2種以上を組み合わせて使用できる。
When the composition for external use of the present invention contains water, the content thereof is preferably 5% by weight or more, more preferably 10% by weight or more, and still more preferably 20% or more, with respect to the total amount of the composition. Moreover, 80 weight% or less is preferable, 70 weight% or less is more preferable, and 50 weight% or less is still more preferable. When the composition for external use of the present invention is an emulsified composition, it may be O / W type or W / O type.
A base or a support | carrier can be used individually by 1 type or in combination of 2 or more types.
添加剤
本発明の組成物には、本発明の効果を損なわない範囲で、医薬品、医薬部外品、又は化粧品等の外用組成物に添加される添加剤、例えば、酸化防止剤、界面活性剤、保存剤、pH調整剤、安定化剤、刺激軽減剤、防腐剤、着色剤、香料、及び/又はパール光沢付与剤等を添加することができる。
Additives In the composition of the present invention, additives that are added to compositions for external use such as pharmaceuticals, quasi-drugs, and cosmetics within the range not impairing the effects of the present invention, such as antioxidants and surfactants. , Preservatives, pH adjusters, stabilizers, irritation reducers, preservatives, colorants, fragrances, and / or pearlescent agents.
酸化防止剤としては、トコフェロール類、ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、没食子酸エステル類などが挙げられる。 Examples of the antioxidant include tocopherols, dibutylhydroxytoluene, butylhydroxyanisole, gallic acid esters and the like.
界面活性剤としては、例えば、ソルビタンモノイソステアレート、ソルビタンモノラウレート、ソルビタンモノパルミテート、ソルビタンモノステアレートのようなソルビタン脂肪酸エステル類;モノステアリン酸プロピレングリコールのようなプロピレングリコール脂肪酸エステル類;ポリオキシエチレン硬化ヒマシ油40(HCO−40)、ポリオキシエチレン硬化ヒマシ油50(HCO−50)、ポリオキシエチレン硬化ヒマシ油60(HCO−60)、及びポリオキシエチレン硬化ヒマシ油80などの硬化ヒマシ油誘導体;モノラウリル酸ポリオキシエチレン(20)ソルビタン(ポリソルベート20)、モノステアリン酸ポリオキシエチレン(20)ソルビタン(ポリソルベート60)、モノオレイン酸ポリオキシエチレン(20)ソルビタン(ポリソルベート80)、及びイソステアリン酸ポリオキシエチレン(20)ソルビタンのようなポリオキシエチレンソルビタン脂肪酸エステル類;ポリオキシエチレンセチルエーテルのようなポリオキシアルキレンアルキルエーテル、(C成分と重なるため削除しました。森);リン脂質、サーファクチン、及びサポニンなどの天然界面活性剤;ステアリン酸ジエチルアミノエチルアミド、及びステアリン酸ジエチルアミノプロピルアミドなどの脂肪酸アミドアミン;トリラウリルアミン、ジメチルステアリルアミン、及びジ-2-エチルヘキシルアミンなどのアルキルアミン;並びにステアリン酸ジメチルアミノプロピルアミド、及びラウリルヒドロキシスルホベタインなどのベタイン系両性界面活性剤などが挙げられる。 Examples of the surfactant include sorbitan fatty acid esters such as sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate; propylene glycol fatty acid esters such as propylene glycol monostearate; Curing of polyoxyethylene hydrogenated castor oil 40 (HCO-40), polyoxyethylene hydrogenated castor oil 50 (HCO-50), polyoxyethylene hydrogenated castor oil 60 (HCO-60), and polyoxyethylene hydrogenated castor oil 80 Castor oil derivative; polyoxyethylene (20) sorbitan monolaurate (polysorbate 20), polyoxyethylene (20) sorbitan monostearate (polysorbate 60), polyoxyethylene monooleate (20 Polyoxyethylene sorbitan fatty acid esters such as sorbitan (polysorbate 80) and polyoxyethylene (20) sorbitan isostearate; polyoxyalkylene alkyl ethers such as polyoxyethylene cetyl ether (removed due to overlapping with component C) Forest); natural surfactants such as phospholipids, surfactins, and saponins; fatty acid amidoamines such as diethylaminoethylamide stearate and diethylaminopropylamide stearate; trilaurylamine, dimethylstearylamine, and di-2-ethylhexyl And alkylamines such as amines; and betaine amphoteric surfactants such as dimethylaminopropylamide stearate and lauryl hydroxysulfobetaine.
pH調整剤としては、例えば、無機酸(塩酸、及び硫酸など)、有機酸(乳酸、乳酸ナトリウム、クエン酸、クエン酸ナトリウム、コハク酸、及びコハク酸ナトリウムなど)、無機塩基(水酸化カリウム、及び水酸化ナトリウムなど)、並びに有機塩基(トリエタノールアミン、ジイソプロパノールアミン、及びトリイソプロパノールアミンなど)などが挙げられる。 Examples of pH adjusters include inorganic acids (such as hydrochloric acid and sulfuric acid), organic acids (such as lactic acid, sodium lactate, citric acid, sodium citrate, succinic acid, and sodium succinate), inorganic bases (potassium hydroxide, And sodium hydroxide), and organic bases (such as triethanolamine, diisopropanolamine, and triisopropanolamine).
防腐剤としては、例えば、デヒドロ酢酸及びその塩、2−メチル−4−イソチアゾリン−3−オン、ブチルカルバミン酸ヨウ化プロピル、クロロブタノール、ソルビン酸及びその塩、及びグリセリン脂肪酸エステル、パラベン類などが挙げられる。 Examples of the preservative include dehydroacetic acid and its salt, 2-methyl-4-isothiazolin-3-one, propyl iodide butylcarbamate, chlorobutanol, sorbic acid and its salt, glycerin fatty acid ester, parabens and the like. Can be mentioned.
安定化剤としては、例えばポリアクリル酸ナトリウム、アスコルビン酸及びその塩類、エリソルビン酸及びその塩類、亜硫酸ナトリウム、二硫化硫黄などが挙げられる。 Examples of the stabilizer include sodium polyacrylate, ascorbic acid and its salts, erythorbic acid and its salts, sodium sulfite, sulfur disulfide and the like.
添加剤は、1種を単独で、又は2種以上を組み合わせて使用できる。 An additive can be used individually by 1 type or in combination of 2 or more types.
その他の薬理活性成分又は生理活性成分
本発明の外用組成物は、本発明の効果を損なわない範囲で、PQQ又はその塩以外の薬理活性成分又は生理活性成分を含むことができる。
PQQ又はその塩以外の薬理活性成分又は生理活性成分の具体例としては、例えば、保湿成分、抗炎症成分、抗菌又は殺菌成分、ペプチド又はその誘導体、アミノ酸又はその誘導体、角質軟化成分、及び収斂成分等が挙げられる。
Other Pharmacologically Active Component or Physiologically Active Component The composition for external use of the present invention can contain a pharmacologically active component or physiologically active component other than PQQ or a salt thereof as long as the effects of the present invention are not impaired.
Specific examples of pharmacologically active ingredients or physiologically active ingredients other than PQQ or salts thereof include, for example, moisturizing ingredients, anti-inflammatory ingredients, antibacterial or bactericidal ingredients, peptides or derivatives thereof, amino acids or derivatives thereof, keratin softening ingredients, and astringent ingredients Etc.
保湿成分としては、例えば、グリセリン、1,3−ブチレングリコール、プロピレングリコール、ポリエチレングリコール、ジプロピレングリコール、ソルビトール、キシリトール、エリスリトール、及びジグリセリンのような多価アルコール;グルコース、マルトース、及びトレハロースのような糖類;ヘパリン類似物質、コンドロイチン硫酸ナトリウム、コラーゲン、エラスチン、ケラチン、キチン、及びキトサンのような高分子化合物;グリシン、及びアスパラギン酸のようなアミノ酸;乳酸ナトリウム、尿素、及びピロリドンカルボン酸ナトリウムのような天然保湿因子;セラミド、コレステロール、及びリン脂
質のような脂質などが挙げられる。
Examples of moisturizing ingredients include polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol, polyethylene glycol, dipropylene glycol, sorbitol, xylitol, erythritol, and diglycerine; glucose, maltose, and trehalose. Macromolecules such as heparin analogs, sodium chondroitin sulfate, collagen, elastin, keratin, chitin, and chitosan; amino acids such as glycine and aspartic acid; such as sodium lactate, urea, and sodium pyrrolidonecarboxylate Natural moisturizing factors; lipids such as ceramide, cholesterol, and phospholipids.
抗炎症成分としては、例えば、植物(例えば、コンフリー)に由来する成分、アラントイン、グリチルリチン酸又はその誘導体、酸化亜鉛、塩酸ピリドキシン、サリチル酸又はその誘導体、及びε-アミノカプロン酸などが挙げられる。 Examples of the anti-inflammatory component include a component derived from a plant (for example, Comfrey), allantoin, glycyrrhizic acid or a derivative thereof, zinc oxide, pyridoxine hydrochloride, salicylic acid or a derivative thereof, and ε-aminocaproic acid.
抗菌又は殺菌成分としては、例えば、クロルヘキシジン、サリチル酸、塩化ベンザルコニウム、アクリノール、イオウ、レゾルシン、エタノール、塩化ベンゼトニウム、アダパレン、過酸化ベンゾイル、クリンダマイシン、クレゾール、グルコン酸及びその誘導体、ポピドンヨード、ヨウ化カリウム、ヨウ素、イソプロピルメチルフェノール、トリクロカルバン、トリクロサン、感光素101号、感光素201号、グリセリン脂肪酸エステル、塩酸アルキルジアミノグリシン、グルコン酸クロルヘキシジン、パラフェノールスルホン酸亜鉛、及びアゼライン酸等が挙げられる。 Antibacterial or bactericidal components include, for example, chlorhexidine, salicylic acid, benzalkonium chloride, acrinol, sulfur, resorcin, ethanol, benzethonium chloride, adapalene, benzoyl peroxide, clindamycin, cresol, gluconic acid and its derivatives, popidone iodine, iodine Potassium iodide, iodine, isopropylmethylphenol, triclocarban, triclosan, photosensitizer 101, photosensitizer 201, glycerin fatty acid ester, alkyldiaminoglycine hydrochloride, chlorhexidine gluconate, zinc paraphenolsulfonate, and azelaic acid .
ペプチド又はその誘導体としては、例えば、ケラチン分解ペプチド、加水分解ケラチン、コラーゲン、魚由来コラーゲン、アテロコラーゲン、ゼラチン、エラスチン、エラスチン分解ペプチド、コラーゲン分解ペプチド、加水分解コラーゲン、塩化ヒドロキシプロピルアンモニウム加水分解コラーゲン、エラスチン分解ペプチド、コンキオリン分解ペプチド、加水分解コンキオリン、シルク蛋白分解ペプチド、加水分解シルク、ラウロイル加水分解シルクナトリウム、大豆蛋白分解ペプチド、加水分解大豆蛋白、小麦蛋白、小麦蛋白分解ペプチド、加水分解小麦蛋白、カゼイン分解ペプチド、並びにアシル化ペプチド(パルミトイルオリゴペプチド、パルミトイルペンタペプチド、及びパルミトイルテトラペプチド等)などが挙げられる。 Peptides or derivatives thereof include, for example, keratin-degrading peptide, hydrolyzed keratin, collagen, fish-derived collagen, atelocollagen, gelatin, elastin, elastin-degrading peptide, collagen-degrading peptide, hydrolyzed collagen, hydroxypropylammonium chloride hydrolyzed collagen, elastin Degraded peptide, conchiolin degrading peptide, hydrolyzed conchiolin, silk proteolytic peptide, hydrolyzed silk, lauroyl hydrolyzed silk sodium, soy proteolytic peptide, hydrolyzed soy protein, wheat protein, wheat proteolytic peptide, hydrolyzed wheat protein, casein Degraded peptides, acylated peptides (palmitoyl oligopeptides, palmitoyl pentapeptides, palmitoyl tetrapeptides, etc.) and the like can be mentioned.
アミノ酸又はその誘導体としては、例えば、ベタイン(トリメチルグリシン)、プロリン、ヒドロキシプロリン、リジン、セリン、グリシン、アラニン、フェニルアラニン、β−アラニン、スレオニン、グルタミン酸、グルタミン、アスパラギン、アスパラギン酸、システイン、シスチン、メチオニン、ロイシン、イソロイシン、バリン、ヒスチジン、タウリン、γ−アミノ酪酸、γ−アミノ−β−ヒドロキシ酪酸、カルニチン、カルノシン、及びクレアチン等が挙げられる。 Examples of amino acids or derivatives thereof include betaine (trimethylglycine), proline, hydroxyproline, lysine, serine, glycine, alanine, phenylalanine, β-alanine, threonine, glutamic acid, glutamine, asparagine, aspartic acid, cysteine, cystine, methionine , Leucine, isoleucine, valine, histidine, taurine, γ-aminobutyric acid, γ-amino-β-hydroxybutyric acid, carnitine, carnosine, creatine and the like.
角質軟化成分としては、例えば、尿素、サリチル酸、グリコール酸、フルーツ酸、フィチン酸、及びイオウなどが挙げられる。 Examples of the keratin softening component include urea, salicylic acid, glycolic acid, fruit acid, phytic acid, and sulfur.
収斂成分としては、例えば、パラフェノールスルホン酸亜鉛、酸化亜鉛、メントール、及びエタノールなどが挙げられる。
紫外線防御成分としては、例えば、ケイ酸亜鉛、ケイ酸セリウム、ケイ酸チタン、酸化亜鉛、酸化ジルコニウム、酸化セリウム、酸化チタン、酸化鉄等の無機化合物、それらの無機化合物を含水ケイ酸、無水ケイ酸、水酸化アルミニウム、マイカやタルク等の無機粉体で被覆したり、ポリアミド、ポリエチレン、ポリエステル、ポリスチレン、ナイロン等の樹脂粉体に複合化したもの、さらにシリコーン油や脂肪酸アルミニウム塩等で処理したものなどが挙げられる。
Examples of the astringent component include zinc paraphenol sulfonate, zinc oxide, menthol, and ethanol.
Examples of the ultraviolet protection component include zinc silicate, cerium silicate, titanium silicate, zinc oxide, zirconium oxide, cerium oxide, titanium oxide, iron oxide and other inorganic compounds, and those inorganic compounds containing hydrous silicic acid and anhydrous silica. Coated with inorganic powder such as acid, aluminum hydroxide, mica and talc, compounded with resin powder such as polyamide, polyethylene, polyester, polystyrene and nylon, and further treated with silicone oil and fatty acid aluminum salt Things.
PQQ又はその塩以外の薬理活性成分又は生理活性成分は、1種を単独で、又は2種以上を組み合わせて使用できる。 Pharmacologically active ingredients or physiologically active ingredients other than PQQ or a salt thereof can be used alone or in combination of two or more.
使用方法
本発明の外用組成物(皮膚外用剤)は、使用対象の皮膚の状態、年齢、性別などによって異なるが、例えば以下の方法で使用すればよい。即ち、1日数回(例えば、約1〜5回、好ましくは1〜3回)、1回当たり適量(例えば、約0.05〜5g)を皮膚に塗布、貼付、又は噴霧などにより適用すればよい。また、PQQ又はその塩の1日使用量が、例えば、約0.0005〜0.05g、好ましくは約0.001〜0.02g、より好ましくは約0.002〜0.01gとなるように組成物を塗布すればよい。また、塗布期間は、特に制限はないが、例えば、約2週間〜6ヶ月、好ましくは約1〜6ヶ月間とすればよい。
本発明の外用組成物は、PQQ又はその塩の生理活性を期待して、種々の皮膚疾患や皮膚トラブルを有する人に好適に使用できる。特に、シワ、タルミを有する人、肌のキメが乱れている人、敏感肌の人が好適な対象となる。また、特に光老化による皮膚トラブルの予防のため、正常な肌を有する人も好適な使用対象となる。
本発明の外用組成物は、紫外線からの皮膚や毛髪の保護、日焼け予防などのための日焼け止め化粧料、紫外線防御用化粧料としても好適に使用することができる。
Method of Use The composition for external use (skin preparation for external use) of the present invention varies depending on the condition, age, sex, etc. of the skin to be used, but may be used, for example, by the following method. That is, if it is applied several times a day (for example, about 1 to 5 times, preferably 1 to 3 times), an appropriate amount (for example, about 0.05 to 5 g) is applied to the skin by application, application, or spraying. Good. Further, the daily usage amount of PQQ or a salt thereof is, for example, about 0.0005 to 0.05 g, preferably about 0.001 to 0.02 g, more preferably about 0.002 to 0.01 g. What is necessary is just to apply | coat a composition. The application period is not particularly limited, and may be, for example, about 2 weeks to 6 months, preferably about 1 to 6 months.
The composition for external use of the present invention can be suitably used for people having various skin diseases and skin troubles, expecting the physiological activity of PQQ or a salt thereof. In particular, people who have wrinkles and tarmi, people whose skin texture is disturbed, and people with sensitive skin are suitable targets. In addition, in order to prevent skin troubles caused by photoaging, people with normal skin are also suitable for use.
The composition for external use of the present invention can also be suitably used as a sunscreen cosmetic for protecting skin and hair from ultraviolet rays, preventing sunburn, and a UV protective cosmetic.
その他
本発明は、(a)PQQ又はその塩を含む組成物(特に、外用組成物)に、(b)紫外線吸収剤を添加することによって、PQQ又はその塩の熱安定性を向上させる方法を包含する。
この方法において、各成分の種類、各成分の含有量、組成物のpH、組成物の性状などは、上記説明した本発明の外用組成物の場合と同じである。
In addition, the present invention provides a method for improving the thermal stability of PQQ or a salt thereof by adding (b) an ultraviolet absorber to a composition (particularly a composition for external use) containing (a) PQQ or a salt thereof. Include.
In this method, the type of each component, the content of each component, the pH of the composition, the properties of the composition, and the like are the same as in the case of the external composition of the present invention described above.
以下、本発明を、実施例を挙げてより詳細に説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in detail, this invention is not limited to these Examples.
熱安定性の評価
表1の組成に従い、(アクリレーツ/アクリル酸(C10−30))クロスポリマーを秤りとり、攪拌しながら水に分散させ、トリエタノールアミンで膨潤し水層とした。一方で、表1の(B)欄に示す紫外線吸収剤をトリエチルヘキサノイン及びポリオキシエチレン硬化ヒマシ油60に80℃で加熱して溶解し、油層とした。ディスパーで水層を攪拌しながら、油層を投入し、T.K.ROBOMICS(PRIMIX社製)を用いて3000rpmで5分間攪拌した。最後にPQQ-2Naを添加し、トリエタノールアミンを用いてpHを調整した後、攪拌した(実施例1〜3)。比較例1は紫外線吸収剤を入れる以外は、実施例1〜3と同様に作製した。実施例1〜3および比較例1の各外用組成物を10mL容量のヘッドスペースバイアルに5gずつ分注し、密閉後、70℃にて2週間保存した。保存前と保存後のサンプル中のPQQ-2Na含有量を、高速液体クロマトグラフィーを用いて定量した。さらに以下に示す式1を用いて残存率を算出し、結果を図1に示した。
PQQ-2Na残存率(%)=(加速試験後のPQQ-2Na含有量/加速試験前のPQQ-2Na含有量)×100 (式1)
Evaluation of Thermal Stability According to the composition of Table 1, the (acrylates / acrylic acid (C10-30)) crosspolymer was weighed, dispersed in water with stirring, and swollen with triethanolamine to form an aqueous layer. On the other hand, the ultraviolet absorber shown in the column (B) of Table 1 was dissolved in triethylhexanoin and polyoxyethylene hydrogenated castor oil 60 by heating at 80 ° C. to obtain an oil layer. While stirring the aqueous layer with a disper, the oil layer was added. K. The mixture was stirred for 5 minutes at 3000 rpm using ROBOMICS (manufactured by PRIMIX). Finally, PQQ-2Na was added, and the pH was adjusted with triethanolamine, followed by stirring (Examples 1 to 3). Comparative Example 1 was prepared in the same manner as in Examples 1 to 3 except that an ultraviolet absorber was added. 5 g of each of the compositions for external use of Examples 1 to 3 and Comparative Example 1 was dispensed into a 10 mL headspace vial, sealed, and stored at 70 ° C. for 2 weeks. The PQQ-2Na content in the sample before and after storage was quantified using high performance liquid chromatography. Furthermore, the residual ratio was calculated using the following formula 1, and the results are shown in FIG.
PQQ-2Na residual ratio (%) = (PQQ-2Na content after acceleration test / PQQ-2Na content before acceleration test) × 100 (Formula 1)
結果を図1に示す。
PQQ-2Naを含む組成物である比較例1においては、PQQ-2Naは75%しか残存していなかった。一方で、PQQ-2Naを含む組成物に、紫外線吸収剤である4−tert−ブチル−4’−メトキシジベンゾイルメタン(パルソール1789)を配合するとPQQ-2Naの残存率は98%まで向上し、殆ど分解しない熱に安定な組成物を作ることに成功した(実施例1)。また、2,4−ビス−{[4−(2−エチル−ヘキシルオキシ)−2−ヒドロキシ]−フェニル}−6−(4−メトキシフェニル)−1,3,5−トリアジン(チノソーブS)、2−[−4−(ジエチルアミノ)−2−ヒドロキシベンゾイル]安息香酸ヘキシルエステル(ユビナールAPlus)を配合することにより、PQQ-2Naの残存率が、それぞれ91%(実施例2)、89%(実施例3)まで上昇した。
The results are shown in Figure 1.
In Comparative Example 1, which is a composition containing PQQ-2Na, only 75% of PQQ-2Na remained. On the other hand, when 4-tert-butyl-4′-methoxydibenzoylmethane (Pulsol 1789), an ultraviolet absorber, is added to the composition containing PQQ-2Na, the residual rate of PQQ-2Na is improved to 98%. A heat-stable composition that hardly decomposes was successfully produced (Example 1). Also, 2,4-bis-{[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (Tinosorb S), By blending 2-[-4- (diethylamino) -2-hydroxybenzoyl] benzoic acid hexyl ester (ubibinal APlus), the residual ratios of PQQ-2Na were 91% (Example 2) and 89% (implementation), respectively. It rose to Example 3).
以上より、(a)PQQ又はその塩を含有する製剤に、(b)紫外線吸収剤を添加することにより、PQQ又はその塩の含有量の低下が抑えられた。 As mentioned above, the fall of content of PQQ or its salt was suppressed by adding (b) ultraviolet absorber to the formulation containing (a) PQQ or its salt.
以下の表2〜5に、本発明の外用組成物の処方例を示す。表中の数値の単位は、w/w%である。
本発明の外用組成物は、安定性が悪いPQQ又はその塩を含みながら、保存安定性に優れるため、商品価値が高いものである。 Since the composition for external use of the present invention contains PQQ or a salt thereof having poor stability and is excellent in storage stability, it has a high commercial value.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013198248A JP6284730B2 (en) | 2013-09-25 | 2013-09-25 | Composition for external use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013198248A JP6284730B2 (en) | 2013-09-25 | 2013-09-25 | Composition for external use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015063487A true JP2015063487A (en) | 2015-04-09 |
JP6284730B2 JP6284730B2 (en) | 2018-02-28 |
Family
ID=52831708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013198248A Active JP6284730B2 (en) | 2013-09-25 | 2013-09-25 | Composition for external use |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6284730B2 (en) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02142713A (en) * | 1988-11-25 | 1990-05-31 | Shiseido Co Ltd | External preparation for skin |
JPH03112912A (en) * | 1989-09-27 | 1991-05-14 | Sanko Seibutsu Kagaku Kenkyusho:Kk | Cosmetic composition |
JPH0820585A (en) * | 1994-07-07 | 1996-01-23 | Mitsubishi Gas Chem Co Inc | Ultraviolet absorber and skin preparation for external use |
JPH0899856A (en) * | 1994-09-29 | 1996-04-16 | Shiseido Co Ltd | Skin external agent |
JPH09249545A (en) * | 1996-03-12 | 1997-09-22 | Shiseido Co Ltd | Skin preparation for external use |
JP2009221154A (en) * | 2008-03-17 | 2009-10-01 | Pola Chem Ind Inc | Interleukin-6 production inhibitor |
JP2010013374A (en) * | 2008-07-02 | 2010-01-21 | Shiseido Co Ltd | Water-containing composition |
JP2011026226A (en) * | 2009-07-23 | 2011-02-10 | Mitsubishi Gas Chemical Co Inc | Method of preserving liquid including pyrroloquinolinequinone |
JP2011246442A (en) * | 2010-04-28 | 2011-12-08 | Rohto Pharmaceutical Co Ltd | Photoaging inhibitor and inhibitor to skin thinning |
JP2012001507A (en) * | 2010-06-18 | 2012-01-05 | Osaka Prefecture Univ | Ptp1b inhibitor, and diabetes treatment agent, skin external pharmaceutical preparation and food containing the same |
JP2012097020A (en) * | 2010-11-01 | 2012-05-24 | Mitsubishi Gas Chemical Co Inc | Method for eliminating singlet oxygen |
JP2012211129A (en) * | 2011-03-23 | 2012-11-01 | Rohto Pharmaceutical Co Ltd | External composition |
JP2012224625A (en) * | 2011-04-07 | 2012-11-15 | Rohto Pharmaceutical Co Ltd | Composition for external application |
JP2013151480A (en) * | 2011-12-26 | 2013-08-08 | Rohto Pharmaceutical Co Ltd | Stabilization method for composition for external use |
-
2013
- 2013-09-25 JP JP2013198248A patent/JP6284730B2/en active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02142713A (en) * | 1988-11-25 | 1990-05-31 | Shiseido Co Ltd | External preparation for skin |
JPH03112912A (en) * | 1989-09-27 | 1991-05-14 | Sanko Seibutsu Kagaku Kenkyusho:Kk | Cosmetic composition |
JPH0820585A (en) * | 1994-07-07 | 1996-01-23 | Mitsubishi Gas Chem Co Inc | Ultraviolet absorber and skin preparation for external use |
JPH0899856A (en) * | 1994-09-29 | 1996-04-16 | Shiseido Co Ltd | Skin external agent |
JPH09249545A (en) * | 1996-03-12 | 1997-09-22 | Shiseido Co Ltd | Skin preparation for external use |
JP2009221154A (en) * | 2008-03-17 | 2009-10-01 | Pola Chem Ind Inc | Interleukin-6 production inhibitor |
JP2010013374A (en) * | 2008-07-02 | 2010-01-21 | Shiseido Co Ltd | Water-containing composition |
JP2011026226A (en) * | 2009-07-23 | 2011-02-10 | Mitsubishi Gas Chemical Co Inc | Method of preserving liquid including pyrroloquinolinequinone |
JP2011246442A (en) * | 2010-04-28 | 2011-12-08 | Rohto Pharmaceutical Co Ltd | Photoaging inhibitor and inhibitor to skin thinning |
JP2012001507A (en) * | 2010-06-18 | 2012-01-05 | Osaka Prefecture Univ | Ptp1b inhibitor, and diabetes treatment agent, skin external pharmaceutical preparation and food containing the same |
JP2012097020A (en) * | 2010-11-01 | 2012-05-24 | Mitsubishi Gas Chemical Co Inc | Method for eliminating singlet oxygen |
JP2012211129A (en) * | 2011-03-23 | 2012-11-01 | Rohto Pharmaceutical Co Ltd | External composition |
JP2012224625A (en) * | 2011-04-07 | 2012-11-15 | Rohto Pharmaceutical Co Ltd | Composition for external application |
JP2013151480A (en) * | 2011-12-26 | 2013-08-08 | Rohto Pharmaceutical Co Ltd | Stabilization method for composition for external use |
Also Published As
Publication number | Publication date |
---|---|
JP6284730B2 (en) | 2018-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5876962B2 (en) | Composition for external use | |
US10835572B2 (en) | Composition for external application | |
JP6430109B2 (en) | Composition for external use | |
JP7084567B2 (en) | Personal care composition comprising a glutathione precursor comprising nicotinamide and an amino acid | |
JP4786630B2 (en) | Topical skin preparation | |
JP7199495B2 (en) | Composition for replenishing young female odor | |
JP6975516B2 (en) | External composition, cosmetics, transdermal absorption promoting composition, method for enhancing transdermal absorbability of active ingredient in external composition, transdermal pharmaceutical and eye drop composition | |
JP2020007375A (en) | Skin external composition | |
JP2018127445A (en) | External composition | |
JP2005060234A (en) | External preparation for skin | |
JP6403487B2 (en) | Topical preparation | |
JP6416473B2 (en) | Composition for external use | |
WO2012137932A1 (en) | Composition for external application | |
JP2018021085A (en) | Composition for external use | |
JP5951277B2 (en) | External composition containing azelaic acid | |
JP2016094361A (en) | External preparation for protection against microparticle matter | |
JP6284729B2 (en) | Composition for external use | |
JP6284730B2 (en) | Composition for external use | |
JP2005060233A (en) | External preparation for skin | |
JP6329757B2 (en) | Composition for external use | |
JPWO2018012157A1 (en) | Melanin production inhibitor, skin lightening agent, fibroblast activating agent, collagen and / or elastin production promoter, and wrinkle improver | |
JP5902410B2 (en) | Composition for external use | |
JP2012036174A (en) | Composition for external application | |
JP2015063486A (en) | External composition | |
JP5734686B2 (en) | Skin external composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160824 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170411 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170502 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170711 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171108 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180131 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6284730 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |